Table 2. Safety Profile of Therapeutic Options in Follicular Lymphoma^a.

Agent	Most common adverse events	Black box warning	Contraindication
Immunomodulatory therapy
Rituximab	Infusion-related reaction, fever, lymphopenia, chills, infection, asthenia	Fatal infusion-related reaction, severe mucocutaneous reaction, HBV reactivation, progressive multifocal leukoencephalopathy	None
Obinutuzumab	Infusion-related reaction, fatigue, neutropenia, cough, URTI, musculoskeletal pain	HBV reactivation, progressive multifocal leukoencephalopathy	Hypersensitivity reaction to obinutuzumab or any of the excipients, including serum sickness with prior obinutuzumab use
Lenalidomide	Cytopenia (neutropenia, thrombocytopenia, anemia, leukopenia), diarrhea, constipation, nausea, fatigue, pyrexia, cough, URTI, rash	Embryofetal toxicity, hematologic toxicity, venous/arterial thromboembolism	Pregnancy Demonstrated severe hypersensitivity to lenalidomide
CAR T-cell therapy
Axicabtagene ciloleucel	Cytopenia (neutropenia, leukopenia, thrombocytopenia, anemia), CRS, fever, hypotension, encephalopathy, tachycardia, fatigue, headache, febrile neutropenia, nausea, infection with unspecified pathogens, decreased appetite, chills, diarrhea, tremor, musculoskeletal pain, cough, hypoxia, constipation, vomiting, arrhythmias, dizziness	CRS, neurologic toxicity	None
Tisagenlecleucel	Cytopenia (neutropenia, leukopenia, thrombocytopenia, anemia), CRS, infections-pathogens unspecified, fatigue, musculoskeletal pain, headache, diarrhea	CRS, neurologic toxicity	None
Bispecific antibody therapy
Mosunetuzumab	Cytopenia (lymphopenia, anemia, leukopenia, neutropenia, thrombocytopenia), CRS, fatigue, rash, pyrexia, headache	CRS	None
EZH2 inhibitor
Tazemetostata	Fatigue, URTI, musculoskeletal pain, nausea, abdominal pain	None	None
PI3K inhibitor
Copanlisib	Hyperglycemia, diarrhea, decreased general strength/energy, hypertension, cytopenia (leukopenia, neutropenia, thrombocytopenia), nausea, lower respiratory tract infection	None	None

Note. CAR T-cell therapy = chimeric antigen receptor T-cell therapy; CRS = cytokine release syndrome; EZH2 = enhancer of zeste homolog 2; HBV = hepatitis B virus; PI3K = phosphoinositide 3 kinase; URTI = upper respiratory tract infection.

^aIncludes wildtype and mutant-type EZH2.